Graphy Publications
Inspiring Innovations & Discoveries
International Journal of Clinical Research & Trials Volume 4 (2019), Article ID 4:IJCRT-131, 05 pages
Meta Analysis
Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis

Jesse A. Kane1, Talha Mehmood1, Irsa Munir1, Haroon Kamran1, Pramod Theetha Kariyanna1, Angelina Zhyvotovska1, Denis Yusupov1, Umer Javed Suleman1, Deborah R. Gustafson2,3 and Samy I. McFarlane1*

1Department of Internal Medicine, Divisions of Cardiovascular Disease and Endocrinology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA

2Department of Neurology, State University of New York - Downstate Medical Center, Brooklyn, NY 11203, USA
3Neuropsychiatric Epidemiology Unit, University of Gothenburg, Gothenburg, Sweden
Prof. Samy I. McFarlane, Divisions of Cardiovascular Disease,and Endocrinology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, 11203, USA, Tel: 718- 270-6707, Fax: 718-270-4488; E-mail:
02 January 2019; 19 January 2019; 21 January 2019
Kane JA, Mehmood T, Munir I, Kamran H, Kariyanna PT, et al. (2019) Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. Int J Clin Res Trials 4: 131. doi:
This work is supported, in part, by the efforts of Dr. Moro O. Salifu M.D., M.P.H., M.B.A., M.A.C.P., Professor and Chairman of Medicine through NIH Grant number S21MD012474.


  1. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL, et al. (2016) Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA 315: 2284-2291. View
  2. Ryan DH, Kahan S (2018) Guideline Recommendations for Obesity Management. Med Clin North Am. 102: 49-63. View
  3. Yang L, Colditz GA (2015) Prevalence of Overweight and Obesity in the United States, 2007-2012. JAMA Intern Med 175: 1412-1413. View
  4. Landsberg L, Troisi R, Parker D, Young JB, Weiss ST (1991) Obesity, blood pressure, and the sympathetic nervous system. Ann Epidemiol 1: 295-303. View
  5. Verma S, Hussain ME (2017) Obesity and diabetes: An update. Diabetes Metab Syndr 11: 73-79. View
  6. Klop B, Elte JW, Cabezas MC (2013) Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5: 1218-1240. View
  7. Schwartz AR, Patil SP, Laffan AM, Polotsky V, Schneider H, et al., (2008) Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc 5: 185-192. View
  8. Apovian CM, Gokce N (2012) Obesity and cardiovascular disease. Circulation 125: 1178-1182. View
  9. Curioni CC, Lourenco PM (2005) Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 29: 1168-1174. View
  10. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, et al. (2011) Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123: 1683-1701. View
  11. Ioannides-Demos LL, Piccenna L, McNeil JJ (2011) Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011: 179674. View
  12. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, et al. (2016) Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA 315: 990-1004. View
  13. Lindgarde F (2000) The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 248: 245-254. View
  14. Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, et al., (2007) Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 30: 27-32. View
  15. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, et al. (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341-1352. View
  16. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, et al. (2013) Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36: 4022-4029. View
  17. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, et al. (2011) A oneyear randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96: 3067-3077. View
  18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. View
  19. Mantel N, Haenszel W (1959) Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease. J Natl Cancer Inst 22:719-48. View
  20. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, et al. (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307: 56-65. View
  21. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB (2012) Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98: 1763- 1777. View
  22. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, et al. (2003) Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23: 1042-1047. View
  23. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, et al. (2005) Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients With Type 2 Diabetes. Diabetes 54: 603-608. View
  24. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, et al. (2001) Long- Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med 134: 1-11. View
  25. Dixon JB, O'Brien PE (2002) Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res 10: 903-910. View
  26. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ (2005) Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293: 43-53. View
  27. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, et al. (2000) Reduction in Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-Induced Weight Loss in Men. Ann Intern Med 133: 92-103. View
  28. Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16: 397-415. View
  29. Klein S, Burke LE, Bray GA, Blair S, Allison DB, et al. (2004) Clinical Implications of Obesity with Specific Focus on Cardiovascular Disease A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation 110: 2952-2967. View
  30. Harp JB (1998) An assessment of the efficacy and safety of orlistat for the long-term management of obesity. The Journal of Nutritional Biochemistry 9: 516-521. View
  31. Gustafson AKC, Rey JA (2013) Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. PT 38: 525-534. View
  32. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, et al., (2014) Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 32: 1178-1188.
  33. Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 84: 1-11. View